• Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (PubMed=12794755).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Pro71fs (c.211delC); Zygosity=Unspecified (PubMed=12794755).
  

PubMed=7834619
Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T.
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Cancer Res. 55:514-517(1995)

PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7
Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T., Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H., Fujii Y., Takahashi T.
Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.
Am. J. Pathol. 159:1345-1352(2001)

PubMed=12794755; DOI=10.1002/ijc.11184
Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.
RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Int. J. Cancer 106:45-51(2003)

PubMed=19806789; DOI=10.3727/096504009789745511
Otsuka S., Hanibuchi M., Ikuta K., Yano S., Goto H., Ogino H., Yamada T., Kakiuchi S., Nishioka Y., Takahashi T., Sone S.
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Oncol. Res. 17:581-591(2009)